Genmab A/S(Nasdaq: GMAB) announced today that the European Commission (EC) granted marketing authorization for TEPKINLY ® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R 2 ) ...
Sinar Daily on MSN
Why hate speech outruns facts on social media
Election periods are usually the time when there is an uptick in politically-driven negative content and fake news on social ...
A mother's unwavering faith in her son, despite a nursery teacher's harsh assessment of him as 'stupid,' is highlighted in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results